Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate versus placebo for bone microarchitecture in osteopenic postmenopausal women
2005-005598-30Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risedronate and Placebo-COD Research Private Ltd in osteopenia (2 arms), sponsored by Sanofi. Primary endpoint: Percent change at 12 months in distal radius trabecular bone volume. Started Mar 2006; status: completed.
02
Drugs
risedronatePlacebo-COD Research Private Ltd
03
Conditions
osteopenia
Beyond the preview
Go deeper on 2005-005598-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005598-30.